Cited 11 times in
Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강대용 | - |
dc.contributor.author | 김경식 | - |
dc.contributor.author | 박미숙 | - |
dc.contributor.author | 박승우 | - |
dc.contributor.author | 박정엽 | - |
dc.contributor.author | 방승민 | - |
dc.contributor.author | 성진실 | - |
dc.contributor.author | 송시영 | - |
dc.contributor.author | 이승우 | - |
dc.contributor.author | 정재복 | - |
dc.date.accessioned | 2015-01-06T16:23:08Z | - |
dc.date.available | 2015-01-06T16:23:08Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/98008 | - |
dc.description.abstract | PURPOSE: There is no established standard treatment for patients with locally advanced biliary tract cancer (BTC). METHODS: We analyzed the treatment results of locally advanced BTC from Jan 1995 to Dec 2010 at single institution of South Korea with retrospective study. One hundred and seventy-six patients were eligible to investigate the treatment response and toxicity. We treated these patients with 5-fluorouracil (5-FU)- or gemcitabine (GEM)-based concurrent chemoradiotherapy (CCRT) or best supportive care (BSC). The primary end point was overall survival. RESULTS: Of these locally advanced BTC patients, 106 patients received CCRT and 70 patients were treated with BSC. The median overall survival was 42.57 weeks (95 % confidence interval [CI], 35.85-49.30) in CCRT group and 13.29 weeks (95 % CI 10.42-16.15) in BSC group (P < 0.001). Nausea and anemia were the most common toxicities observed. CONCLUSIONS: Patients with locally advanced BTC who were treated with 5-FU-based or GEM-based CCRT seem to have a better survival than those who received BSC. The treatment-related toxicity was mild. GEM-based or 5-FU-based CCRT showed similar survival advantages. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 191~198 | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antimetabolites, Antineoplastic/therapeutic use* | - |
dc.subject.MESH | Biliary Tract Neoplasms/mortality | - |
dc.subject.MESH | Biliary Tract Neoplasms/therapy* | - |
dc.subject.MESH | Chemoradiotherapy*/adverse effects | - |
dc.subject.MESH | Deoxycytidine/adverse effects | - |
dc.subject.MESH | Deoxycytidine/analogs & derivatives* | - |
dc.subject.MESH | Deoxycytidine/therapeutic use | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/adverse effects | - |
dc.subject.MESH | Fluorouracil/therapeutic use* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Retrospective Studies | - |
dc.title | Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Seung Woo Yi | - |
dc.contributor.googleauthor | Dae Ryong Kang | - |
dc.contributor.googleauthor | Kyung Sik Kim | - |
dc.contributor.googleauthor | Mi Suk Park | - |
dc.contributor.googleauthor | Jinsil Seong | - |
dc.contributor.googleauthor | Jeong Youp Park | - |
dc.contributor.googleauthor | Seung Min Bang | - |
dc.contributor.googleauthor | Si Young Song | - |
dc.contributor.googleauthor | Jae Bock Chung | - |
dc.contributor.googleauthor | Seung Woo Park | - |
dc.identifier.doi | 10.1007/s00280-013-2340-5 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00299 | - |
dc.contributor.localId | A01463 | - |
dc.contributor.localId | A01551 | - |
dc.contributor.localId | A01647 | - |
dc.contributor.localId | A01786 | - |
dc.contributor.localId | A01956 | - |
dc.contributor.localId | A02035 | - |
dc.contributor.localId | A02920 | - |
dc.contributor.localId | A03706 | - |
dc.contributor.localId | A00009 | - |
dc.relation.journalcode | J00437 | - |
dc.identifier.eissn | 1432-0843 | - |
dc.identifier.pmid | 24322374 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs00280-013-2340-5 | - |
dc.subject.keyword | Biliary tract cancer | - |
dc.subject.keyword | Concurrent chemoradiation | - |
dc.subject.keyword | GB cancer | - |
dc.subject.keyword | Locally advanced | - |
dc.contributor.alternativeName | Kang, Dae Ryong | - |
dc.contributor.alternativeName | Kim, Kyung Sik | - |
dc.contributor.alternativeName | Park, Mi Sook | - |
dc.contributor.alternativeName | Park, Seung Woo | - |
dc.contributor.alternativeName | Park, Jeong Youp | - |
dc.contributor.alternativeName | Bang, Seung Min | - |
dc.contributor.alternativeName | Seong, Jin Sil | - |
dc.contributor.alternativeName | Song, Si Young | - |
dc.contributor.alternativeName | Yi, Seung Woo | - |
dc.contributor.alternativeName | Chung, Jae Bock | - |
dc.contributor.affiliatedAuthor | Kim, Kyung Sik | - |
dc.contributor.affiliatedAuthor | Park, Mi-Suk | - |
dc.contributor.affiliatedAuthor | Park, Seung Woo | - |
dc.contributor.affiliatedAuthor | Park, Jeong Youp | - |
dc.contributor.affiliatedAuthor | Bang, Seung Min | - |
dc.contributor.affiliatedAuthor | Seong, Jin Sil | - |
dc.contributor.affiliatedAuthor | Song, Si Young | - |
dc.contributor.affiliatedAuthor | Yi, Seung Woo | - |
dc.contributor.affiliatedAuthor | Chung, Jae Bock | - |
dc.contributor.affiliatedAuthor | Kang, Dae Ryong | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 73 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 191 | - |
dc.citation.endPage | 198 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.73(1) : 191-198, 2014 | - |
dc.identifier.rimsid | 54328 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.